Robuta

Although Regeneron has been playing catch-up in the oncology field for years, a pipeline built on next-wave promises could push the boundaries.

Despite promising pipelines, most new launches are missing sales targets, forcing pharmas to rethink sales strategies.

From popular weight loss drugs to lifesaving cancer therapies, recent pharma deals show the industry is doubling down on manufacturing capacity to meet demand.

COVID-19 slowed many studies — but the war could further strain clinical trials worldwide.

The CEO of Cullinan Oncology is taking a small biotech to the next step and believes the temporary financial barriers are smaller than scientific progress.

Late-stage GLP-1 candidates from Eli Lilly, Novo Nordisk and Amgen have a combined net present value of $68 billion.

Sales of Eli Lilly’s Kisunla, and Eisai and Biogen’s Leqembi are on the rise as doctors grow more confident and new dosing options ease treatment hurdles.

While a couple drugs have reached the market, their effects are still modest, and experts say a true paradigm shift is still a ways off.

Among tariffs, pricing policies and ongoing negotiations, pharma leaders can’t help but address their dealings with the Trump administration in third-quarter...

The company’s new partnership with Pfizer is worth up to $530 million — and could be just the beginning.